TCL Archive Letter to the Editors: Loss Of ET2 Would Be Disheartening, Member Of Study Section Says February 20, 1998
TCL Archive Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer October 25, 2013